Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neuramis Volume Lidocaine is a hyaluronic acid-based dermal filler developed by Medytox. It is classified as a medical device and consists of cross-linked hyaluronic acid (20 mg/mL) combined with 0.3% lidocaine for pain reduction during injection. The filler is produced using Medytox's proprietary SHAPE (Stabilized Hyaluronic Acid Purification Enhancement) technology, which employs a two-step cross-linking process to ensure high purity and minimal residual cross-linking agents like BDDE (butanediol diglycidyl ether). It is specifically designed for deep facial volumization, including mid-face volume restoration, cheek and chin augmentation, and the correction of deep facial folds. The effects typically persist for 6 to 18 months, and the product utilizes FDA-approved hyaluronic acid and is certified by the European Directorate for the Quality of Medicines (EDQM).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + lidocaine (Medytox Inc.).